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ABSTRACT 
 
Harms of treatment with cholesterol-lowering drugs in children: A systematic 
review of the published literature 
 
Background: Some clinical guidelines recommend pharmacologic treatment for children 
with hyperlipidemia. These medications decrease cholesterol levels, but their side effects 
or potential harms in children are not well understood. 
 
Objective: To systematically review published trials of cholesterol-lowering medications 
in children and quantify their harms. 
 
Design/Methods: A comprehensive search was used to identify prospective studies 
evaluating the use of cholesterol-lowering drugs compared to controls in children with 
hyperlipidemia. Titles and abstracts were independently reviewed by authors and 
appropriate articles were fully evaluated. Blinded investigators completed quality 
assessments of included studies, followed by data extraction of all reported side effects or 
other harms using a standardized form. 
 
Results:  A systematic search of the published literature identified 1070 titles and 
abstracts for potential inclusion. The 17 articles that met final inclusion criteria varied 
widely in quality, were generally not powered to detect adverse effects, and more than 
half disclosed pharmaceutical company sponsorship. None followed subjects for  6 
years. All included subjects (N=1604) with a probable diagnosis of heterozygous familial 
hyperlipidemia Studies evaluated the following therapies: HMG CoA reductase inhibitors 
(statins) versus placebo (10 studies), bile acid sequestrants (4 studies), bile acid 
sequestrants as add-on therapy to statins (1 study), statins as add-on therapy to bile acid 
sequestrants (1 study), and ezetemibe (1 study).  Statins generally had similar harms to 
placebo, except in 7 of the 11 studies there was an increase in muscle symptoms or 
abnormal muscle enzyme laboratory values. Additionally, 3 of 5 statin studies evaluating 
dihydroepiandrosterone (DHEAS) reported significant changes in hormone levels. Two 
of 5 studies that evaluated bile acid sequestrants reported an increase in gastrointestinal 
symptoms. Ezetimibe therapy added to statin therapy increased myalgias (5.6% combined 
therapy vs. 0.8% placebo, p=0.03). 
 
Conclusions: Published studies of pharmacotherapy for hyperlipidemia in children are 
limited by small numbers, short follow-up periods, and a unique population. The 
available studies suggest that statins, bile acid sequestrants, and cholesterol absorption 
blockers all have associated side effects. Unfortunately, currently available studies have 
not fully assessed longer term harms, complicating treatment decisions.       
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INTRODUCTION  
In adults, cardiovascular disease is the leading cause of death and morbidity in the 
United States
[1]
.  Evidence has shown that high levels of total cholesterol and low density 
lipoprotein cholesterol can lead to the formation of atherosclerotic plaques and is one of 
the leading risk factors for coronary heart disease
[2]
.  Lipid measurements in adults have 
been proven to be effective in identifying those at risk, and early treatment has been 
shown to decrease the incidence of coronary heart disease in persons with abnormal 
lipids
[2]
. 
Children are not immune from high cholesterol either, as elevated cholesterol 
levels in children have gradually become more common with the growing obesity 
epidemic, especially here in the United States. Evidence has shown that atherosclerotic 
plaques can form at a young age
[3]
.  However, it is unclear if this leads to increased 
cardiac related mortality once these children become adults.  This lack of evidence 
creates difficult questions that care providers for children must face: “Should I treat this 
child with high cholesterol? And, “If I use medication to treat this child, could I be 
causing more harm than good?”  
In an effort to help answer one of these questions, we performed a systematic 
review of available research to look at the harms associated with the medications used to 
treat high cholesterol in children. 
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BACKGROUND 
Dyslipidemia – What is It? 
 Lipids are fat soluble compounds that naturally occur in the human body, and 
serve a wide array of biological functions, including energy storage, molecular signaling, 
and manufacture of cell membranes.  When lipid levels are abnormally high however, 
they can play a key role in accelerating human disease processes, especially in helping to 
form plaques in arterial blood vessels, a syndrome commonly known as atherosclerosis. 
These elevations of lipids and subsequent atherosclerosis are one of the leading risk 
factors and a predictor of cardiac related mortality in adults.  These abnormal levels of 
total cholesterol, low-density lipoprotein cholesterol (LDL), triglycerides, or deficiency 
of high-density lipoprotein cholesterol (HDL) are all caused by disorders of lipoprotein 
metabolism that can be termed “dyslipidemias”, and can be either acquired or familial[4].  
Risk factors for dyslipidemia include established family history, diabetes, nephritic 
syndrome, and hypothyroidism
[5]
. 
 
Why are dyslipidemias medically relevant? 
 In light of this basic background information, it is important to consider why 
dyslipidemias are considered relevant to the medical field.  Numerous studies have 
demonstrated that the most consistent and strongest risk factors for cardiovascular disease 
in adults include elevated LDL, low HDL, hypertension, diabetes mellitus, cigarette use, 
obesity, and especially increasing age
[1,6]
.  The most notable of these studies, the 
Framingham Study, was a large scale, long-term follow-up study that helped identify the 
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risk factors for heart disease and has recently been adapted to help calculate a patient’s 
risk of dying within ten years from heart disease based on their individual risk factors
[7]
.  
 Obviously, a person’s age or family history cannot be altered; however several of 
the other risk factors mentioned are amenable to some degree of change. As 
cardiovascular disease is the leading cause of death among adults in the United States, it 
is important to recognize and attempt to treat/correct any of these other risk factors that 
can be altered
[4,8]
. 
 Lipid disorders are one of the modifiable risk factors that can be altered through 
medical treatment and lifestyle changes.  Early detection and treatment of abnormal lipid 
levels in adults has been proven to help decrease cardiovascular related deaths
[5]
.  This 
has resulted in the National Cholesterol Education Program’s (NCEP’s) recommendation 
to screen once every 5 years starting at 20 years of age, with increasing frequency as a 
person grows older or if they have abnormal cholesterol levels
[7]
.  
 
 
How is dyslipidemia defined? 
 As mentioned above, dyslipidemias come in four basic categories: elevated total 
cholesterol levels, elevated LDL cholesterol levels, elevated triglyceride levels, and low 
HDL cholesterol.  Cholesterol levels are obtained by measurements in blood samples.  
Total cholesterol, triglycerides, and HDL are measured directly, while LDL levels can be 
measured directly or calculated via the Friedewald equation, which uses measurements of 
total cholesterol, HDL, and triglycerides to estimate LDL concentrations
[8]
. 
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 In general, the definitions of dyslipidemia are based on previously studied 
population norms for serum cholesterol levels, and serum levels falling outside the 95
th
 
percentile are often considered “abnormal” or dyslipidemic.  For example, the American 
Association of Clinical Endocrinologists considers a person to have a dyslipidemia if 
his/her serum total cholesterol level is greater than or equal to 240mg/dL
[8]
.  A person can 
also be said to have a dyslipidemia if his/her serum HDL cholesterol is less than 
35mg/dL, serum LDL cholesterol is greater than or equal to 160mg/dL, or their serum 
triglycerides are greater than 200mg/dL
[8]
.  These specific numbers may vary slightly 
between various professional organizations.   
 It is important to note that while these specific number cutoffs may give the 
appearance that dyslipidemias are dichotomous (either normal or abnormal), this is 
actually not the case.  It is more appropriate to view them in combination with the other 
previously mentioned risk factors as continuous risk factors for cardiac related death, 
with serum concentrations at these levels or worse only increasing an individual’s risk of 
heart disease death. This point is further illustrated by the National Cholesterol Education 
Program’s newest classification method, which can be found in Table 1 below[7].   
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Table 1 
NCEP ATIII Classification of 
LDL, Total, and HDL Cholesterol 
Levels    
LDL Cholesterol    
 <100  Optimal 
 100-129  
Near Optimal/above 
optimal 
 130-159  Borderline High 
 160-189  High 
 >/= 190  Very High 
Total Cholesterol    
 <200  Desirable 
 200-239  Borderline High 
 >/= 240  High 
HDL Cholesterol    
 <40  Low 
 >/=60  High 
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What are the current recommendations for treating dyslipidemias? 
As previously mentioned, elevated lipids act as a continuous risk factor and a 
predictor of cardiac related mortality.  With this in mind, treating elevated lipid levels has 
become a major priority of primary care providers and specialists across the US. In 
general, treatment of dyslipidemia is aimed at lowering lipid levels, with the idea being 
that cardiac related mortality will be subsequently reduced. Treatment can be either 
through pharmacological or therapeutic life-style changes.  
Often, before pharmacologic interventions are necessary, many guidelines 
recommend therapeutic lifestyle changes as a first line approach to treat high cholesterol.  
Therapeutic lifestyle changes include the use of exercise in combination with a low-fat, 
low-cholesterol diet, such as the American Heart Association Step I diet, as the first step 
in treating most pediatric dyslipidemia
[4]
.  Dietary changes, especially in conjunction with 
exercise, are often used as first line therapies in helping to battle against dyslipidemia.  
For this reason, the NCEP also recommends dietary changes, increased physical activity, 
and weight reduction prior to initiating pharmacological therapy in their newest set of 
guidelines
[7]
.  
Should therapeutic lifestyle changes alone not be effective and a physician deem 
in necessary to use medications to treat dyslipidemias, numerous pharmacologic 
treatment options exist.  The most commonly prescribed medication for treating 
dyslipidemias in the United States are 3-Hydroxy-3-methyl-glutaryl Coenzyme A 
Reductase Inhibitors, which are more commonly known as “statins”.  These medications 
decrease LDL concentrations by decreasing intracellular cholesterol levels and up-
regulating LDL receptors, which in turn clears more LDL from circulation, and can 
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reduce LDL levels by 20-50%
[1,9]
.  In addition, they are the one intervention that evidence 
has shown to not only reduce LDL levels, but are also effective in cholesterol plaque 
stabilization and been found to reduce cardiac risk
[10]
.  
Other cholesterol-lowering medications commonly used include: 1)bile acid-
binding resins, which work by binding cholesterol in bile acids in the intestinal lumen, 
preventing their re-uptake into circulation and lowering cholesterol levels by 10-20% 
when used alone or in combination with other medications
[1,11]
; 2)  Niacin (nicotinic 
acid) lowers both LDL and triglycerides while at the same time increasing HDL by 
decreasing hepatic production of very low-density lipoprotein (VLDL), however its use is 
limited by its harsh side effects, which have been found to be excessively common
[1,12]
; 
3) Cholesterol absorption blockers are an emerging treatment for dyslipidemias and act 
by reducing absorption in the small intestine 
[1]
.  and 4) fibrates reduce triglyceride levels 
by acting on VLDL 
[1]
.    
 
When is treatment of dyslipidemias recommended? 
The National Cholesterol Education Program’s (NCEP) executive panel 
recommends treatment modalities on the basis of a combination of cholesterol levels and 
a patient’s risk factors[7].  Their recommendations are also the same as those used by the 
American Association of Clinical Endocrinologists (AACE)
[8]
.  Both of these 
organizations’ recommendations focus primarily on LDL cholesterol levels, as extensive 
research has shown that elevated LDL levels are a major risk factor for heart disease
[7,8]
.  
Both organizations provide basic LDL goals on a scale that varies in accordance with a 
patient’s of number cardiac-related of risk factors. The higher the number of patient’s risk 
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factors, the lower their target LDL goal should be, as risk greatly increases with multiple 
risk factors and even moderately increased LDL levels
[7,8]
.  
Table 2 shows the current clinical guidelines for treatment as described by both 
the NCEP and the AACE
[7,8]
.  These clinical guidelines stress the importance of adjusting 
treatment modalities and LDL target levels on the basis each individual patient’s risk 
factors, including current LDL level.  This personalized approach targets each individual 
patient and incorporates all the patient’s risk factors, helping simplify a physician’s 
treatment decisions.  
 
 
TABLE 2. AACE and NCEP treatment Recommendations. 
 
 LDL level and intervention recommended    
Coronary 
Artery 
Disease Risk 
Factors 
Therapeutic 
Lifestyle 
changes 
Pharmacologic 
Therapy 
Goal 
LDL     
<2 >/= 160 >/= 190 < 160     
>/= 2 >/= 130 >/= 160 < 130     
With 
Atherosclerotic 
Disease >/= 100 >/= 130 < 100     
With Type 2 
Diabetes >/= 100 >/= 130 < 100     
        
Risk Factors: Smoking, Hypertension, HDL <40, Family History of CAD, Age (men >45, women >55) 
  - 12 - 
What are the harms of the drugs used to treat dyslipidemias?   
As with nearly any medical therapy, there are harms associated with 
pharmacologic treatments used to lower lipids.  They have been studied extensively with 
the same substantial safety monitoring and experimentation that any drug must go 
through to be FDA approved.  The side effects associated with these medications can 
vary in both frequency and severity depending on drug class.  For example, bile acid-
binding resins are known to often cause gastrointestinal issues such as abdominal pain, 
flatulence, diarrhea, nausea, and vomiting
[1]
.  Cholesterol absorption blockers like 
ezetimibe are also known to cause similar GI complaints
[1]
.   Fibrates are known to cause 
myopathies leading to muscle breakdown and rhabdomyolysis, especially when 
combined with other cholesterol lowering medications such as statins
[1]
.  Statins have 
been shown to increase hepatic transaminase levels, which are often used as surrogate 
markers for liver damage
[1]
.  Statins are also known to cause muscle aches, cramps, 
creatinine kinase elevations, and rhabdomyolysis
[1]
.  Niacin is known to have a high 
incidence of side effects, and is often not recommended to patients for that very reason.  
Its side effects can include but are not limited to flushing, liver failure, myopathies, 
glucose intolerance, and hyperuricemia
[1]
.  These are just a few of the side effects 
commonly seen with lipid lowering medications.
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Dyslipidemia in Children/Adolescents 
 The majority of the clinical burden of dyslipidemias occurs in adulthood; however 
recent research increasingly indicates that the processes of atherosclerotic cardiovascular 
disease may begin much earlier in life and progresses through one’s life span[1,3].  In 
children, total cholesterol levels increase from birth, stabilize around two years of age, 
peak before puberty, and show a slight decline during adolescence
[5]
. 
 Currently, no specific evidence exists that supports a particular level of childhood 
cholesterol is predictive of adult cardiovascular disease, rendering evidence-based 
recommendations for cholesterol screening in childhood elusive.  However, research in 
children and adolescents demonstrates that risk factors for adult cardiovascular disease 
may be present as early as childhood, especially given the increasing prevalence of 
obesity
[1]
.  Current estimates by the Centers for Disease Control based on data collected 
by the National Health and Nutrition Examination Survey (NHANES) from 1999–2006 
show that up to 20.3% of children between the ages of 12 and 19 have abnormal lipid 
levels, including 42.9% of children that were obese
[13,14]
. 
 Research has also shown that atherosclerotic lesions begin in childhood.  
Specifically, the Bogalusa Heart Study found atherosclerotic lesions at autopsy with 
increased frequency in children with increased lipid levels
[1,15]
.  In this study, data on 
thousands of children and young adults was collected through cross-sectional studies to 
evaluate cardiovascular risk factors dating back as far as 1973
[3]
.  Following any deaths 
of study subjects for any reason (mostly trauma), researchers requested permission from 
family members to perform autopsies on the deceased, looking for evidence of 
atherosclerosis in the aorta and coronary arteries
[3]
.  The study showed that fatty streaks 
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of atherosclerosis could be found in the abdominal aorta at 3 years of age and coronary 
arteries at 10 years of age
[3,4]
.  However, this evidence merely shows that fatty streaks can 
form in childhood.  It fails to directly link childhood lipid levels to health outcomes in 
adulthood, leaving the adult coronary heart disease risk attributable specifically to 
dyslipidemia during childhood unknown
[5]
.   
 While it is increasingly clear that cholesterol concentrations can be elevated 
during childhood and adolescence, no long-term studies have been able to demonstrate a 
direct relationship between lipid levels measured in childhood and coronary heart disease 
and cardiovascular related death in adults
[4]
.  Parts of the Bogalusa studies followed their 
patients for up to 17 years
[3]
, but this would still put the oldest patients in the study in 
their mid-30s at last follow-up, at least a decade short of when the majority of cardiac 
related deaths would start to occur.  Further, many of the drug trials in children 
demonstrate through serum cholesterol measurements that the medications being used are 
effective at lowering serum cholesterol levels. However, these studies do not follow their 
subjects into adulthood to determine whether this reduction in serum cholesterol levels 
actually reduces heart disease deaths.  
 A recent cohort study performed by Dr Paul Franks and his colleagues followed 
over 4,800 children from an Indian reservation through the age of 55 in an effort to link 
causes of death to obesity and metabolic syndromes such as dyslipidemia and 
hypertension in childhood
[16]
.  The study did show that premature death from all 
“endogenous” causes (cause was disease or self-inflicted injury) was 73% more common 
in the highest BMI group than the lowest BMI group, however there was no correlation 
when they looked at cholesterol levels
[16]
.  Also, no specific comparisons were made for 
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cardiac related deaths only.  This lack of evidence further increases questions on whether 
treating cholesterol in childhood has any effect on reducing cardiac related deaths in 
adulthood. 
For now, we are left to speculate on the relationship between lipid levels in 
childhood and the ultimate outcome of interest, cardiovascular related mortality in 
adulthood.  It is logical to assume that children with cholesterol problems would become 
adults with cholesterol problems, and some research has shown that between 40-55% of 
children with dyslipidemias go on to become adults with dyslipidemias
[4]
.  Given that 
adults with cholesterol problems are at higher risk for heart disease, one could speculate 
that these children would be at higher risk in adulthood.  However, it is also important to 
consider the other side of that same argument.  As approximately 50% of children with 
dyslipidemias go on not to have dyslipidemias in adulthood, is it necessary to treat all 
children with dyslipidemias, especially given the lack of evidence that this intervention 
reduces cardiac related deaths in adulthood? 
With all of these arguments in mind, the potential relationship between childhood 
and adult dyslipidemias has been deemed enough evidence by some children’s healthcare 
organizations place an emphasis on primary prevention of dyslipidemias via screening in 
childhood
[1,4]
.  Optimal screening programs would identify persons with progressive 
atherosclerosis that are most at risk of cardiovascular disease in adulthood. However, we 
currently lack noninvasive, inexpensive clinical tools to look for atherosclerosis, leaving 
serum cholesterol levels as a surrogate marker to calculate long-term risk
[1]
. This lack of 
direct evidence continues to be a point of contention, further clouding the picture.  The 
lack of direct evidence also results in different opinions on whether or not screening in 
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childhood should be conducted, as demonstrated by the varying recommendations given 
by medical agencies that can be found below.  
 
 
How do experts define dyslipidemia in children? 
 
The currently available definitions for dyslipidemia in children do not vary 
greatly from those definitions in adults, and are also constructed to identify patients who 
would theoretically be at higher risk for cardiovascular related morbidity and mortality.  
The parameters currently used for dyslipidemias in children were created following the 
Lipid Research Clinics Prevalence Study conducted in the 1970s, which studied 
population distributions of lipid levels in children and adolescents
[5,17]
.  In pediatric 
patients, dyslipidemia is commonly defined as a total cholesterol level of >200mg/dL and 
LDL >130mg/dL, as these values correspond to the 95
th
 percentile as observed in the 
Lipid Research Clinics Prevalence Study
[5,17]
.  The American Heart Association has gone 
on to define triglyceride concentrations of >150mg/dL and HDL concentrations of 
<35mg/dL to also be considered abnormal in children and adolescents
[1]
.  Like adults, 
screening is performed by measuring total cholesterol and HDL concentrations via 
fasting or non-fasting blood sample; however it is important to note that triglyceride and 
LDL levels can only be calculated or measured accurately if a fasting sample is taken
[5]
.    
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What methods are used for treating dyslipidemias specifically in children? 
 The current treatment modalities used for the treatment of dyslipidemias in 
children do not vary greatly from those used in adults found on page 6 above.  Many 
recommend therapeutic lifestyle changes including diet and exercise as the first line 
approach, followed by pharmacologic intervention
[1,4,18]
.  However, evidence has shown 
that therapeutic lifestyle changes have minimal effectiveness in children, leaving many 
providers instead to opt for the pharmacological approach
[5]
.  The lipid-lowering 
medications currently used in children include statins, fibrates, cholesterol absorption 
blockers, niacin, and bile acid-binding resins.  The most commonly used medication class 
is the statins, while the least commonly used medications are the fibrates and niacin due 
to their side effect profiles as noted in adults
[1]
.  The side effect profiles for all of these 
medications in adults and children are thought to be similar, however current research is 
limited.  Using available research studies where these medications were used in children, 
we conducted a systematic review to better look at these effects.  Results can be found 
below. 
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Current Recommendations for Screening in Children/Adolescents 
 In light of this background information, the current recommendations for 
screening and treating children for dyslipidemias put out by varying organizations can be 
found below. 
 
American Academy of Pediatrics (AAP) 
 The newest set of recommendations for pediatricians, released in 2008, requests 
that pediatricians initiate a “lifelong approach” to cardiovascular disease prevention in 
their patients by tracking lipid levels and the progression of atherosclerosis into 
adulthood
[1]
.  While the AAP readily admits that firm evidence-based recommendations 
for cholesterol screening in children are not currently available, they also think that 
increased cholesterol concentration in childhood increases the risk of later cardiovascular 
disease
[1]
.  The AAP’s newest recommendations suggest cholesterol screening for all 
overweight children, as targeted screening only towards persons with a positive family 
history missed somewhere from 30% to 60% of the population that needed screening
[1]
.    
The specific recommendations of the AAP, as taken from Pediatrics, the official journal 
of the AAP, states the following
[1]
: 
 1. The population approach to a healthful diet should be recommended to all 
children older than 2 years according to Dietary Guidelines for Americans. This approach 
includes the use of low-fat dairy products. For children between 12 months and 2 years of 
age for whom overweight or obesity is a concern or who have a family history of obesity, 
dyslipidemia, or CVD, the use of reduced-fat milk would be appropriate. 
 
2. The individual approach for children and adolescents at higher risk for CVD 
and with a high concentration of LDL includes recommended changes in diet with 
nutritional counseling and other lifestyle interventions such as increased physical activity. 
 
3. The most current recommendation is to screen children and adolescents with a 
positive family history of dyslipidemia or premature (</=55 years of age for men and 
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</=65 years of age for women) CVD or dyslipidemia. It is also recommended that 
pediatric patients for whom family history is not known or those with other CVD risk 
factors, such as overweight (BMI  >/=85th percentile, <95th percentile), obesity (BMI 
>/=95th percentile), hypertension (blood pressure >/=95th percentile), cigarette smoking, 
or diabetes mellitus, be screened with a fasting lipid profile. 
 
4. For these children, the first screening should take place after 2 years of age but 
no later than 10 years of age. Screening before 2 years of age is not recommended. 
 
5. A fasting lipid profile is the recommended approach to screening, because there 
is no currently available noninvasive method to assess atherosclerotic CVD in children. 
This screening should occur in the context of well-child and health maintenance visits. If 
values are within the reference range on initial screening, the patient should be retested in 
3 to 5 years. 
 
6. For pediatric patients who are overweight or obese and have a high triglyceride 
concentration or low HDL concentration, weight management is the primary treatment, 
which includes improvement of diet with nutritional counseling and increased physical 
activity to produce improved energy balance. 
 
7. For patients 8 years and older with an LDL concentration of >/=190 mg/dL (or 
>/=160 mg/dL with a family history of early heart disease or >/=2 additional risk factors 
present or >/=130 mg/dL if diabetes mellitus is present), pharmacologic intervention 
should be considered. The initial goal is to lower LDL concentration to <160 mg/dL. 
However, targets as low as 130 mg/dL or even 110 mg/dL may be warranted when there 
is a strong family history of CVD, especially with other risk factors including obesity, 
diabetes mellitus, the metabolic syndrome, and other higher-risk situations. 
 
 
US Preventive Services Task Force 
 The US Preventive Services Task Force (USPSTF) determined that there was 
good evidence that children with lipid disorders are at higher risk for becoming adults 
with lipid disorders, with some studies showing that up to 45-60% of children with 
dyslipidemias on to become adults with dyslipidemias
[4]
.  However, the Task Force also 
concluded that there are critical research gaps with respect to benefits of screening and 
treatment on long term reduction of cardiovascular disease, harms of potential 
pharmacologic interventions, or that diet or exercise interventions in childhood lead to 
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improved lipid levels or better outcomes in adulthood
[5]
.  The Task Force agreed that 
children with familial dyslipidemias would be most likely to benefit from screening, but 
also determined that information acquired through family history could be unreliable and 
failed to detect somewhere between 30% and 60%  of children with elevated lipid 
levels
[4,5]
.  Further, drug treatment of dyslipidemias in childhood has only been shown to 
be effective specifically in familial monogenic dyslipidemias, and intensive diet therapy 
and counseling were shown to only be effective up until cessation of counseling
[4]
. 
 With all of this in mind, the Task Force failed to find sufficient evidence to 
recommend for or against screening, and gave lipid screening in children/adolescents less 
than age 20 an “I” (insufficient) ranking[5], and concluded overall that the effect of 
screening and treatment of childhood dyslipidemia with respect to prevention of 
cardiovascular disease and death in adulthood could not be addressed because of lack of 
evidence and long term studies
[4]
. 
 
American Heart Association 
 The American Heart Association revised its most recent set of guidelines with 
respect to dyslipidemia screening and treatment in children and adolescents in 2007.  
Their initial recommendations, made in 2003, suggested that screening occur only in 
patients with a positive family history
[1]
.  Specifically, children greater than two years of 
age with a family history of early heart disease (<55 years) should receive a fasting lipid 
screening, while those whose parents had a total cholesterol level of >/=240 mg/dL 
should receive a total cholesterol screen
[19]
.  In 2007, the recommendations were updated 
to recommend screening to all children who were overweight or obese, regardless of 
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family history
[5]
.  The guidelines also lay out an ideal diet consisting of fruits, vegetables, 
whole grains, fish, low-fat dairy products, reduced intake of fruit juice and sugar-
sweetened drinks, and reduced salt in combination with increased physical activity in 
order to help reduce lipid levels and fight obesity in childhood
[1]
.  
 
American Academy of Family Physicians 
 When treating children, it is also important to consider the opinions and 
guidelines of family practitioners, as they also treat a large portion of the pediatric 
population.  One of the most recent articles published with respect to lipid screening and 
treatment in the American Family Physician
[19]
, the journal of the American Academy of 
Family Physicians, did not lay out any specific recommendations for their practitioners.  
Instead, the article presented the recommendations of the American Heart Association, 
the American Academy of Pediatrics, and the US Preventive Services Task Force
[19]
. 
However, the articles does state that it is likely that the number needed to treat to prevent 
one premature death from this condition would be extremely high and involve years of 
treatment for many persons who would not benefit
[19]
, a key point that is overlooked by 
the AAP in their most recent recommendations.  According to the Framingham study, the 
risk for having a heart attack greatly increases at 55 years of age in men and 65 in 
women
[7]
, meaning that treatment would have to occur for decades in order to help reduce 
the risk. Further, as it is unknown what percentage of children with dyslipidemias would 
actually suffer from heart disease related death if untreated, it is impossible to know what 
percentage of children would receive unnecessary treatment and suffer any possible 
harms the treatments may cause. 
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 The article goes on to present numerous resources to be used by providers on the 
subject, and stresses the importance of physical activity and healthy lifestyle in helping 
fight the obesity epidemic in the United States, saying: “Family physicians should be 
advocates in their communities for changes that promote building physical activity into 
daily life. Such changes include programs that encourage children to walk and bike to 
school; efforts to build sidewalks, greenways, and bike paths; planning for healthy, walk-
able neighborhoods; and support for the development of parks and playgrounds” [19]. 
 
Focused Clinical Question 
In light of this background information, it is apparent that there is some evidence 
to suggest that abnormal lipid levels do develop in childhood and may continue into 
adulthood.  However, it is unclear as to whether screening and treating these disorders in 
childhood will result in any changes in our most important outcomes measure: reduction 
in cardiovascular related mortality in adulthood.  Even though no intervention in 
childhood has been proven to be beneficial in reducing cardiac mortality in adulthood, 
there is a logical basis for why it could be beneficial and should be considered if there is 
no harm caused by the treatment itself.  With that in mind, we found and applied the 
available evidence in an effort to answer a related question that may help in making the 
decision as to whether we should treat lipid disorders in childhood.  Specifically, in 
children/adolescents with dyslipidemia, what are the harms associated with 
pharmacological therapy when compared to control groups that use no intervention, 
therapeutic lifestyle changes, or placebo?
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METHODS 
Population 
 To properly study the harms associated with pharmacological treatment in 
children vs. placebo or non-pharmacologic therapy, we chose to study a population 
comprised of children ages 0 to 18 years.  We selected this age group because current 
treatment recommendations are unclear, varying from one professional group to the 
other.  We focused our study on this population in an effort to compile these studies and 
create a result with much more power. 
 Following review of the papers pulled for full article review, we limited the 
population to those persons in which the lipid disorder was the primary medical 
condition.  We did not include studies in which the majority of the patients had other 
debilitating illnesses, as these disturbances would be more likely to contribute to adverse 
events when compared to the pharmacologic interventions themselves, which is the goal 
of our study.  For example, illnesses resulting in kidney or liver failure were specifically 
not considered, as these disturbances would most likely be responsible for multiple other 
morbidities and increase the likelihood for complications with any pharmacologic 
intervention as they are the major organs responsible for drug metabolism. 
 
Intervention 
 We focused our literature review on pharmacologic therapy with lipid-lowering or 
altering agents.  Specifically, drug classes to be included are: statins (HMG co-A 
Reductase Inhibitors), fibrates, niacin, bile acid sequestrants, and cholesterol absorption 
blockers.  We did not consider procedural interventions such as plasma exchange, 
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apheresis, and liver transplantation that have been previously tried.  The pharmacologic 
interventions mentioned will be compared to individuals managed conservatively with 
therapeutic lifestyle changes such as diet and exercise, individuals taking a placebo, or 
individuals to whom no intervention is given. 
 
Outcomes 
 The outcomes we examined were adverse events related to treatment with these 
agents in our population.  The term “adverse events” can be very broad and encompass 
numerous different outcomes, so we chose to focus on those events that most directly 
related to treatment or were common side effects of the medications as demonstrated in 
adults.  Outcomes we considered included allergic reactions, muscle 
myopathies/myalgias, liver or renal failure, excessive flushing, other skin rashes, GI 
distress requiring hospitalization or medical treatment, anxiety or depression requiring 
psycho-social therapy or medical treatment, adverse drug interactions, or any other 
serious side effect associated with the pharmacologic interventions being studied. Any 
laboratory anomalies reported were also included. Side effects included could be reported 
by the patient, researcher, or treating physician. 
 
Time Frame 
 Though many of the pharmacologic agents currently used to treat lipid disorders 
have been available for decades, the statin class was not introduced to the United States’ 
market until 1987
[20]
. Given that statins are currently the most commonly prescribed 
agents for lipid disorders in the United States, we chose to focus our search for studies 
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that have been published within the statin era.  Additionally, each study included had to 
have participants enrolled, on treatment, and followed for at least one month during the 
intervention.   
 
Publication Types 
 To maximize the usefulness of this review to the medical field, only primary 
research studies were considered.  No editorials, reviews, or letters were evaluated or 
included in our review.  Specific study types that were included were randomized 
controlled trials and cohort studies as they employ control groups to help lower potential 
for confounding and various other biases, thus allowing them to show associations in the 
relationship between intervention and outcome.  Cross-sectional and open label studies 
were also considered, but their inclusion was dependent on having sufficient control 
groups and meeting all other inclusion criteria. Case control studies were also considered.  
Only published studies were considered due to availability. 
 
Inclusion/Exclusion Criteria 
 Table 3 lists the inclusion and exclusion criteria, which were based on the 
population, intervention, outcomes, timeframe, and publication types previously 
discussed.  Studies included in the systematic review were published since 1987 and 
available in English.  Each study had to give results as to adverse events in persons 
eighteen years of age and younger, and were not accepted if they did not specifically give 
adverse events for this age group separately from those occurring in older individuals.  
Studies focusing on those persons affected by other major medical complications that 
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would be likely to increase the rate of adverse events were also not considered.  Only 
studies that included one of the pharmacologic interventions previously mentioned were 
included.  Lastly, study types considered were randomized controlled trials, cohort 
studies, cross-sectional studies, and case control studies.   
  
Table 3. Inclusion/Exclusion Criteria applied to each study. 
 
Category   Include    Exclude 
Research 
Designs  
*Randomized controlled trial 
*Prospective/retrospective cohort  
*Cross-sectional 
*Case control studies 
*Reviews 
*Letters 
*Editorials 
Population  
*Children ages 0 – 18 
*Patients with dyslipidemia as primary 
problem 
 
*Persons Older than 18 
*Patients with homozygous familial 
dyslipidemias 
*Patients with other primary 
disorders 
Study 
Characteristics 
*Published Studies 
*Available in English 
*Concomitant control group 
*Must discuss adverse events 
 
*Unpublished studies  
*Studies not available in English 
*Studies without concomitant 
control group 
*No discussion of adverse events 
Date   *Studies published since 1987# 
 
*Studies performed before 1987 
Interventions  
 
*Pharmacologic treatment for 
hyperlipidemia or dyslipidemia 
*Studies without pharmacologic 
intervention 
*non-pharmacologic interventions 
such as plasma exchange, 
apheresis, or liver transplant 
 
# Note – Statins first introduced to US market in 1987 
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Search Strategy 
 NOTE: Exact search terms and limits used can be found in Table 4. 
 
Databases  
 To fully search all the available publications and material on the topic, three 
separate databases were used.  The decision was made to search both the Medline and 
EMBASE databases due to their comprehensive nature, and the International 
Pharmaceutical Abstracts database as the intervention we desired was pharmacologic. 
 
Search Terms 
 The search terms used were targeted at achieving the desired population (age 0-
18), medical affliction (some lipid disorder), and the intervention.  To find the 
population, the terms chosen were “child” OR “adolescent” OR “pediatric”.  The terms 
aimed at capturing lipid disorders were “hyperlipidemia” OR “hypercholesterolemia” OR 
“dyslipidemia”.  Finally, multiple terms were used to include the multiple possible 
pharmacologic interventions for these disorders: “atorvastatin” OR “pravastatin” OR 
“lovastatin” OR “rosuvastatin” OR “fluvastatin” OR “simvastatin” OR “hmg CoA 
reductase inhibitors” OR “bile acid sequestrant” OR “cholestyramine” OR “colestipol” 
OR “colesevelam” OR “fibrate” OR “fenofibrate” OR “clofibrate” OR “niacin” OR 
“drug therapy” OR “anticholesterolemic agents” OR “antilipemic agents”.  This list of 
pharmacologic terms includes drug names, drug classes, and just drug therapies in 
general to be fully comprehensive.  Each of the terms was separated by “OR” as 
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indicated, with the categories of population, disorder, and intervention all separated by 
“AND” in an effort to ensure that each result found included each of the three parts.  
 
Limits 
Limits were applied on the search to capture the proper time frame and ensure its 
availability in English.  The time frame was set to include all studies PUBLISHED since 
January 1, 1987 up until the time of the first abstracts were reviewed on April 1, 2009. 
 
 
Table 4. Exact Search Terms and Limits used. 
Search Terms and Limits    
     
Age Terms Disability/Illness Terms Intervention Terms Limits  
Child hyperlipidemia atorvastatin Available in English  
Adolescent hypercholesterolemia pravastatin Published date after January 1, 1987  
Pediatric dyslipidemia lovastatin   
  rosuvastatin   
  fluvastatin   
  simvastatin   
  hmg coa reductase inhibitors   
  bile acid sequestrant   
  cholestyramine   
  colestipol   
  colesevelam   
  fibrate   
  fenofibrate   
  clofibrate   
  niacin   
  drug therapy   
  anticholesterolemic agents   
  antilipemic agents   
     
Note: Terms in each column were separated by "OR", while the columns were separated from each other by "AND" 
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Quality Criteria   
 The quality of each study considered for inclusion was also evaluated and graded 
by two reviewers per study.  The decision was made to grade the quality of these studies 
according to Downs/Black Criteria as originally seen in the Journal of Epidemiology and 
Community Health in 1998 (checklist available in Appendix 1)
[21]
, due to their 
comprehensiveness and ability to accommodate heterogeneous study types.  Each study 
was reviewed separately by two masked individuals, who applied the Downs/Black 
Criteria and recorded the quality grades accordingly.  The two scores assigned for each 
study were then averaged to give the final score.  Both Pearson Pairwise Correlations and 
weighted Kappa values were calculated in order to help ensure there was high inter-rater 
agreement in quality grading. 
 According to the Downs/Black system, points are rewarded on the basis of 
parameters such as reporting of basic study demographics, disclosure of possible biases 
and confounders, internal and external validity measures, and up to five total points on 
the basis of study size/power.  A total of 32 points are possible, with a higher point total 
indicating higher quality.  Point values in the single digits would indicate studies of poor 
quality that contained major flaws, while studies with point totals in the mid to upper 
twenties and lower thirties would indicate good quality studies which have no major 
flaws or errors.  
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Article Selection 
 Following completion of the search of the aforementioned databases using the 
search strategy described, two separate researchers each read all of the titles and 
abstracts.  Any article that could be relevant was noted and later reviewed in full.  
Abstracts that were not related or did not fit Inclusion/Exclusion Criteria were discarded.  
An article did not need to be pulled by both researchers to be reviewed, meaning that any 
article selected by either researcher was pulled for full text review.   
 Each article pulled was then reviewed independently by two separate authors or 
investigators, who applied the inclusion/exclusion criteria to it in order to determine 
whether or not it could be included in the review. If an article was deemed to pass the 
inclusion and exclusion criteria by both persons, it was then considered for the review.  
The quality criteria previously discussed were applied to these articles, and each article 
was given an overall numerical grade based on the results of the Down’s questionnaire 
previously described and available in Appendix 1.  We then abstracted results and 
evidence from the articles and put it into evidence tables to quantify the results and 
present them in a clear and concise manner.  The evidence table used with results 
included can be found in Appendix 2.  Following this process, each of the articles 
selected and evidence abstracted underwent a secondary review by two different 
researchers than those who originally performed the reviews to verify the appropriateness 
of the articles selected, ensure the quality of the articles selected, and verify that the 
information was properly quantified into the evidence tables.  Each of the separate 
reviewers then met to help draw final conclusions on the data collected and determined 
its significance in the medical field. 
  - 31 - 
RESULTS 
Search Results   NOTE: Search results can be found summarized in Figure 1.   
 Using the search terms, criteria, and databases mentioned above, the initial search 
was performed and returned 1179 titles; 878 of those were from Pubmed, 255 from 
Embase, and 46 from the International Pharmaceuticals Abstracts database.  A brief 
initial review of the title and abstracts found 109 duplicate titles, leaving 1070 unique 
articles for further review and application of inclusion/exclusion criteria.  Each of these 
titles and abstracts were read by two individuals, and as previously stated, any article 
suggested by either reviewer that could be relevant was pulled for full text review.  Of 
these 1070 articles, 934 were excluded for various reasons or they were not original data 
on the topic, leaving 136 articles that were pulled for full text review.   
 Each of these 136 articles was individually reviewed, and the Inclusion/Exclusion 
Criteria previously discussed (Table 3) were applied.  An agreement by both researchers 
on each article was reached for whether or not to include each article and a reason for its 
exclusion.  Of the 136 articles, 17 were selected for final inclusion into the systematic 
review.  Eleven of the 109 excluded articles were excluded because they were case 
reports, 27 were excluded because they were review articles or guidelines not containing 
original data, 9 articles were based on duplicate data from already included primary 
studies, 44 did not fit the proper age range, 17 had inadequate control groups, four did not 
treat with medications, and seven had no mention of any adverse events.   
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Figure 1. Search Results. 
 
1179 Total Citations Found
109 Duplicates
878 Pubmed
255 Embase
46 IPA (International 
Pharmaceutical Abstracts)
1070 Distinct Articles
(Double Review)
934 excluded – not original data on topic
136 for full text review
119 Excluded
(Double review and application of 
Inclusion/Exclusion Criteria)
17 Included in Final Results
(4 total readers, 2 per article
- Data Extraction and Quality Grading)
- 11 were Case Reports
-27 were review articles/guidelines/ 
letters/ not original data
- 9 based on Duplicate Data
- 44 had patients of improper ages
- 17 had inadequate control groups
- 4 did not use medications
- 7 did not discuss adverse events
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Article Details and Demographics 
 The articles found are briefly discussed below.  Full details are available in the 
data extraction table (Appendix 2).  
 
Study Types 
Of the 17 articles that met all inclusion criteria and included in the final 
systematic review, 9 were blinded randomized controlled trials
[22-30]
, one was a double-
armed study with randomized controlled trial and case control arms
[31]
, one was a double-
armed randomized controlled trial with blinded and open label arms
[32]
, three were 
randomized controlled trials that were open label studies
[33-35]
, one was a case control 
study
[36]
, one was a prospective cohort study
[37]
, and one was a crossover trial.
[11]
   
 
Medication Class 
 In the 17 included articles, medication classes studied included HMG CoA 
reductase inhibitors (statins), bile acid sequestrants, and cholesterol absorption blockers.  
Eleven of the 17 articles studied statins; 10 versus placebo or diet therapy
[22-27,30,31,35,36]
 
and one as an add-on therapy to bile acid sequestrant.
[11]
  Of the other 6 included studies, 
5 explored bile acid sequestrants (4 as monotherapy
[23,32-34]
 and one as add-on therapy to 
a statin
[37]
), and only one studied the cholesterol absorption blocker ezetimibe, which was 
studied as add-on therapy to a statin.
[29]
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Length of Follow-up 
 Following administration of the intervention, patients were followed for varying 
lengths of time.  Follow-up varied from 1 month
[35]
 up to 70 months.
[34]
  Eight of the 
studies had a follow-up period of at least one year
[26-28,30,32-34,36]
, while only three had a 
follow-up of three months or less.
[24,25,35]
 
 
Patient Demographics 
 A total of 1,604 study subjects participated in the studies that were included in the 
final results, 897 subjects were members of the intervention group, while 707 were part 
of the control groups.  The subjects’ ages ranged from one year in one study[33] to 
eighteen years in four studies.
[11,30,31,35]
  Each of the 17 studies included patients of at 
least ten years of age, while only three studies included patients younger than six.
[33,34,36]
  
There was a slightly higher percentage of males that participated in studies (~60% male 
vs. ~40% female).  It should be noted however, that one study did not report sex
[34]
, one 
study had only female participants
[22]
, and two studies had only male participants.
[25,27]
 
 
Study Sponsorship 
 Of the 17 included studies, 10 disclosed pharmaceutical sponsorship.  Five studies 
were funded in part by contributions from Merck
[22,23,25,27,29]
, 3 by Bristol-Myers 
Squibb
[24,28,30]
, one by Pfizer
[26]
, and one by Upjohn
[32]
.  One of the studies sponsored by 
Merck was also co-sponsored by Schering-Plough Pharmaceuticals
[29]
.  Each of the 
studies sponsored by Merck included a statin as either the intervention or as part of the 
control group, while studies funded by Bristol-Myers Squibb included both statins and 
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bile acid sequestrants. The study funded by Pfizer used atorvastatin as the intervention, 
and Upjohn funded a study on the bile acid sequestrant Colestipol.  
 
Quality Grading 
 Quality grading was performed by two separate individuals according to the 
Downs/Black criteria (Appendix 1) as described in the Methods section.  Scores are 
reported individually and as a mean in the Data Extraction form, Appendix 2, with a 
higher score indicating stronger quality of the work.  Out of a possible 32, the highest 
average score was 26, which was the grade given to two studies
[25]
, and ten of the 
seventeen studies had an average score of at least 20
[11, 22-28,30,32]
.  The lowest average 
score for any study was determined to be 8
[37]
, while no other study had a quality grade 
worse than 12.5.  Also of note, none of the studies received additional quality points for 
power based on sample size according to the Downs/Black Criteria, indicating that none 
of the studies had adequate sample sizes to measure small differences between 
intervention and control groups.  
 To measure inter-observer reliability between quality graders, a weighted kappa 
value was measured and calculated.  This value was found to be 0.48 (p=0.0002), 
indicating a moderate degree of agreement between observers
[38]
.  The Pearsons 
Correlations were also calculated to look at inter-observer agreement between graders.  
All of the correlations were found to be between +0.77 and +0.95, indicating a high 
degree of positive relationships between the values. Ten of the 17 articles graded had a 
Downs/Black score difference of 2 or less (out of the possible 32) from the 2 evaluators 
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per study
[22,25-30,35-37]
, while the largest single difference seen by the separate reviewers 
was 6 points and occurred only on one occasion
[33]
.  
 
Study Size 
 The final studies included varied greatly with respect to sample size; however, 
they were all smaller studies.  Only six of the seventeen studies had more than 100 total 
subjects enrolled when you combined the control and intervention groups
[25-27,29-31]
, and 6 
of the seventeen studies had less than 50 total subjects
[11,33-37]
.  Only 2 of the 17 studies 
had more than 200 total subjects
[29,30]
, with the largest study having 248 total subjects
[29]
.  
Conversely, the smallest study had only 13 total subjects 
[37]
.  With respect to the 
intervention group sizes, the largest study had 140 subjects
[26]
, while the smallest had 
only 4 in the intervention group
[37]
.  Control group sizes varied from 122 subjects
[29]
 to 
8
[36]
.  
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Harms Data   
 All safety parameters monitored for and harms found are available in Appendix 2. 
In total, intervention groups had 418 side effects noted as compared to 317 side effects 
noted in control groups (a 31.86% increase). 
 
Statins  
 As previously mentioned, eleven of the seventeen studies in the final results used 
statins in the intervention group; ten as monotherapy
[22-27,30,31,35,36]
 and one as an add-on 
therapy to a bile-acid sequestrant.
[11]
  
 The majority of these studies had extensive monitoring for harms and laboratory 
anomalies.  All of the studies monitored subjects by physical examination and vital signs, 
and 10 of the eleven had some type of laboratory testing.  For example, all of the studies 
except for two
[11,36]
, also monitored liver function via AST and ALT and the muscle 
enzyme CK.  Six of the studies monitored hemoglobin and hematocrit
[11,22-26]
, three 
monitored thyroid function via TSH
[24,25,27]
, five measured the androgen precursor 
DHEAS
[22,23,25,27,30]
, five monitored cortisol 
[22-25,30]
, and four monitored 
LH/FSH
[22,23,27,30]
.  Other studies monitored routine serum chemistries
[11,23-25]
, bilirubin 
levels
[24,25]
, urinalysis
[23,25]
, measured menstrual cycle lengths
[22,30]
, or paid special 
attention to sexual maturation
[27,30]
.   
 It is important to note however, that not all of the studies indicated that they 
regularly questioned patients for adverse events/side effects.  Two of the studies
[30,31]
 
make no mention of patient reported harms, and three additional studies reported the 
harms only as reported through the physician
[24,27,35,36]
, though there is indication that the 
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physicians in these studies were asking patients about possible side effects.  The 
remaining five studies specifically mentioned harms as reported directly from the 
patients
[11,23,25,26]
. 
 Overall, the side effects in statins were very similar to those found in the control 
groups.  In total, there were 283 recorded adverse events in the intervention groups where 
statins were used vs. 191 in the control groups (NOTE – there were 561 total patients in 
intervention groups vs. 387 in control groups).  Two of the statin studies found no side 
effects
[31,36]
, another found only two cases of elevated AST and ALT
[35]
, and a fourth 
study found only four elevations in CK that were not accompanied by muscle pain or 
myalgias
[30]
.   Seven of the eleven total studies investigating statins showed elevations in 
either AST/ALT or CK
[23-27,30,35]
, while only two of the nine studies that measured AST, 
ALT, and CK did not find any elevations.  Elevations in AST/ALT ranged from 3 times 
the upper limit of the normal value
[23]
 to 10 times the upper limit of the normal value
[35]
. 
Subjects in four of these studies experienced cramps or muscle pains
[11,23,25,27]
, three of 
which were accompanied by CK elevations more than 2 times the upper limit of 
normal
[23,25,27]
.  The fourth study did not measure CK as part of their safety parameters.
[11]
  
Subjects receiving statins experienced GI complaints such as 2 total incidences of 
flatulence and bloating
[11,23]
, 4 experienced nausea and vomiting
[22,24]
, 4 experienced 
diarrhea
[22,27]
, one subject had constipation
[11]
, and one subject had heartburn
[25]
.  
However, the incidences of these harms were relatively similar to their control groups, 
with 5 patients experiencing flatulence, 3 persons experienced nausea and vomiting, 2 
experienced diarrhea, 8 experienced constipation, and one experienced heartburn. In 
addition, twenty total subjects in both the intervention and control groups of six of studies 
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experienced incidences of abdominal pain
[11,22-24,26,27,]
.  It is also worth noting that of the 
side effects in control groups, all five of the patients with flatulence, 7 of the eight with 
constipation, and 8 of the 20 with abdominal pain were subjects in the dual therapy study, 
where the control group was taking colestipol monotherapy.
[11]
  Studies also reported that 
patients experienced many generalized complaints including headache, fever, fatigue, 
sleep disorders, and skeletal pains, all of which are listed and quantified in Appendix 2.   
It is important to note however, that while these finding were all noted and were 
found at slightly increased rates when compared to control groups, almost none of them 
were found to be statistically significant, due largely to the small study sizes. However, 
there were several studies that found side effects of statins that were statistically 
significant when compared to control groups.  The study conducted by Lambert et al. 
showed statistically significant increases in both AST and CK in the intervention group, 
as well as statistically significant increases in the androgen precursor 
dehydroepiandrosterone sulfate (DHEAS)
 [25]
. AST and CK were 17% elevated in the 
intervention group, with a P value of p=0.0008, while DHEAS level was decreased in the 
10mg dosing group (p=0.0165)
 [25]
.  This study also found statistically significant changes 
in cortisol; it increased cortisol levels in the intervention group at lower doses (p=0.0099) 
and decreased it at higher dosages (p=0.0206)
 [25]
.  Two other studies also showed 
statistically significant changes in DHEAS, both showing statistically significant 
decreases when compared to control groups, both with P values less than 0.05
[23,27]
. In 
total, five of the studies that used statins as the intervention group measured 
DHEAS
[22,23,25,27,30]
, three of which showed statistically significant alterations in levels in 
the intervention group
[23,25,27]
. 
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There was one additional study that demonstrated statistically significant 
differences between intervention and control groups
[22]
.  This study showed statistically 
significant decreases in systolic blood pressure and LH (Leutinizing Hormone) in the 
placebo group as opposed to the intervention group.  These decreases in the control group 
created statistically significant differences between control and intervention group, but 
there were no changes at all noted in these parameters in the intervention group.   
 With respect to the absolute number of physical complaints, studies did 
demonstrate increased numbers of patient complaints in the intervention groups when 
compared to their controls.  There were 216 total physical complaints in the intervention 
group, compared to 152 in the control group. This increased number of complaints was 
not statistically significant, but they were found to be higher in all but two of the seven 
studies that reported finding physical complaints
[11,30]
, leaving their clinical significance 
uncertain. 
 
Bile Acid Sequestrants  
 Five of the seventeen studies included in the final results used a bile acid 
sequestrant as the intervention; four as monotherapy vs. placebo or diet control
[28,32-34,]
, 
and one in combination with a statin vs. statin monotherapy as the control group
[37]
.  Two 
of the five studies used the bile acid sequestrant colestipol
[32,33]
, while the other three 
used the bile acid sequestrant cholestyramine 
[28,34,37]
.   
 Each of these studies looked at various harms.  One study looked only at height 
and weight measurements
[33]
, while others were much more extensive, looking at serum 
levels of Vitamins A, B12, D, and E, liver function tests (AST/ALT), sexual maturation 
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and hormones, hematology, thyroid studies, bone age, iron studies, folate, zinc, and 
carotenoids.  Only two of the five studies made note of patient reported physical 
complaints
[28,32]
. 
 Safety monitoring revealed that two of the five studies showed increased 
occurrences of multiple GI side effects, side effects which included: three cases of 
abdominal pain, one case of flatulence, two cases of constipation, three cases of diarrhea, 
four instances of nausea, one episode of vomiting, one case of heartburn, one case of loss 
of appetite, and even one case of intestinal obstruction, though this was not thought to be 
secondary to the intervention
[28,32]
.  Patients in control groups only experienced 1 episode 
of vomiting and two episodes of abdominal pain
[28]
.  Two of the studies also showed 
minor changes in weight when compared to the control group
[32,34]
, and both of the 
studies that monitored folate levels showed increases in folate
[28,32]
.  One study noted a 
statistically significant increases in homocysteine, with P value <0.05
[28]
.  Two of these 
studies reported no adverse events
[33,37]
.   
 
Cholesterol Absorption Blockers 
 Only one study included in the final results used a cholesterol absorption blocker 
(ezetimibe) as the intervention, and it used ezetimibe 10mg in combination with a statin 
as the intervention, while placebo in combination with a statin was used as the control
[29]
.  
With respect to harms, researchers monitored physical exam findings such as height, 
weight, menstrual cycle or menstrual changes, and any physical complaints
[29]
.  They also 
monitored laboratory tests such as CBC, serum chemistries (BMP/CMP), thyroid 
function, sex hormone levels, protein, albumin, electrolytes such as calcium and 
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phosphorus, liver function tests (AST/ALT), CK levels, and monitored kidney and 
urinary changes via routine urinalysis
[29]
.     
 This strict monitoring found increased levels of side effects and 
differences in laboratory tests in the intervention group when compared to the control 
group.  Specifically, there were increased levels of GI side effects such as abdominal pain 
(6 vs. 3), nausea (8 vs. 4),  and diarrhea (9 vs. 3)
 [29]
.  The intervention group also showed 
increased CK levels on laboratory testing and increases in ALT levels (6 vs. 3)
 [29]
.  There 
were also various episodes of other physical complaints such as headache, acne, flu-like 
symptoms, sinusitis and pharyngitis, which were found in comparable numbers in both 
intervention and control groups
[29]
.     
With that in mind, there was one statistically significant harm found when 
comparing ezetimibe and statin combination therapy to the control group of statin 
monotherapy: myalgias
[29]
.  In the intervention group, 5.6% of patients experienced 
myalgias, compared to only 0.8% of the control group (p = 0.03)
 [29]
. 
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CONCLUSIONS/DISCUSSION 
When considering the problem of dyslipidemias in children, there are two major 
factors that should be considered; whether screening should be performed routinely for 
lipid abnormalities in childhood and whether treatment should be initiated if a 
dyslipidemia is found.  
 When determining to what degree screening for dyslipidemias in children should 
be performed, there seems to be two different schools of thought. As found and detailed 
in pages 18-19 above, the AAP favors a wider-scaled screening approach. The AAP’s 
recommendations are somewhat supported by the evidence, however the evidence is not 
strong enough to recommend the wide-scale screening that the AAP indicates.  For 
example, in their recommendations #3 and #4, the AAP recommends that all overweight 
children should be screened between the ages of 2 and 10.  They make these 
recommendations on the evidence from the Bogalusa Heart Study
[3]
, which as previously 
discussed found atherosclerotic lesions in children at autopsy developing at a young age.  
However, it should be noted that no reliable screening mechanism currently exists that 
can look directly for atherosclerosis in large or small vessels, leaving serum cholesterol 
levels as our only screening tool. 
 The AAP also made their recommendations on the basis of evidence found in 
studies by Dr Tamir et al
[39] 
and Dr Hickman et al
[14]
. Dr Tamir’s work in the Lipid 
Research Clinics Program Prevalence Study showed that serum lipid levels increase in 
childhood until the age of 2, at which point they reach “similar” levels to those seen in 
young adults
[39]
.  Dr Hickman’s work as part of the Third National Health and Nutrition 
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Examination Survey (NHANES) showed that total cholesterol levels usually peaked 
between 9 and 11 years of age at approximately 171mg/dL
[14]
.   
Further research performed by Dr Hickman and colleagues as part of NHANES 
showed that cholesterol levels decrease from these levels during pubertal development by 
approximately 10mg/dL on average and slowly increase into adulthood
[14]
.  Given that 
these levels often decrease without intervention, with some studies showing that 
approximately half of dyslipidemic children will not be dyslipidemic as adults
[4]
, testing 
during this time period is likely not necessary on the wide-scale basis that the AAP 
recommends.  Further, while some of the studies used by the AAP in creating their 
guidelines did find a correlation between serum lipid levels in childhood and 
adulthood
[40]
, none of these studies, nor any other cited by the AAP demonstrate a 
correlation between serum lipid concentrations in childhood and cardiac-related death in 
adulthood.  Also, no study to date has demonstrated that treatment of children with 
dyslipidemias reduces cardiac-related death in adulthood. These sentiments are shared by 
the USPSTF, who also concluded that currently available evidence is insufficient to 
recommend screening on a wide-scale basis
[5].
 
With respect to treatment of lipid abnormalities in childhood, the evidence found 
in available studies suggests that children using lipid-lowering medications have 
increased absolute numbers of side effects compared to children using placebo, 
therapeutic lifestyle changes, or no intervention (418 events/laboratory anomalies vs. 
317).  The studies also demonstrate that the side effect profiles in children of each 
medication subclass are comparable to those found in adults, however the overall lack of 
data is a major issue and makes this a difficult conclusion to make.  As expected given 
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their side effect profiles in adults, statins gave increased muscle symptoms such as pain, 
cramping, and myopathies, and showed elevations of the liver enzymes AST and ALT on 
serum testing.  Bile acid sequestrants such as colestipol and cholestyramine showed 
increased numbers of gastrointestinal symptoms such as abdominal pain, diarrhea, 
constipation, nausea, vomiting, bloating, and flatulence.  The one study using the 
cholesterol absorption blocker ezetimibe showed increased incidence of myalgias.   
 As previously noted however, only five of the seventeen total studies found 
statistically different numbers of side effects, despite the consistent trends in that 
direction.  There are many reasons that could explain a lack of statistically significant 
findings in these studies.  The first and most obvious explanation would be because there 
truly are no differences between control and intervention groups, and that the side effects 
experienced would have occurred even without medical treatment.  However, given the 
limited number of available studies, the limited number of study participants, and shorten 
length of both intervention and follow-up, it is possible that differences do indeed exist 
but are not readily apparent due to these study limitations.   
 Though the studies showed increased numbers of side effects in the intervention 
groups, the limited size and duration of these studies also make it difficult to determine 
whether these studies have any true clinical significance that would affect treatment 
decisions made by practicing clinicians.  A clinician may look at these studies, see a 
higher number of absolute events, and decide not to use a medication in a child.  
However, the percentage of events occurring in intervention group vs. control groups was 
similar, which could lead another physician to assume the medications were safe in 
children and prescribe them for treatment.  The combined lack of statistical significance 
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and unknown clinical experience makes treatment decisions that clinicians make on a 
regular basis challenging.   
 Another issue that may explain the lack of differences may be the lack of 
standardized reporting and measuring of harms.  As mentioned above, some of the 
studies went through extensive protocols to monitor patients for laboratory anomalies and 
physical complaints, while others checked only height and weight.  The studies that 
regularly asked patients about physical complaints and had more extensive laboratory 
monitoring reported more adverse events, while those that undertook less strenuous 
monitoring reported less harms and or no harms at all. More strenuous monitoring and 
following of patient reported harms should be used in safety studies in the future to fully 
gauge the number of side effects these medications could be causing. 
 Another key issue with available research is the short length of medication usage 
and follow-up.  Subjects in the included studies received at most 5 years of treatment 
while they were being followed, while in fact these interventions would likely need to be 
continued for decades in order to reduce cardiac events.  For example, 3 of the 5 studies 
that looked for it found statistically significant alterations of dehydroepiandrosterone 
sulfate (DHEAS) with statin usage.  It currently remains uncertain as to whether these 
were solely laboratory abnormalities or whether there is actually potential for morbidity 
such as stunted growth and maturation or precocious puberty over longer time periods.  
To determine this, patients taking statins would need to be monitored until they had 
finished growth, development, and sexual maturation.  This would take longer than the 5 
years or less over which all seventeen of these studies were conducted.   
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 In short, the debate about whether treatment of lipid disorders is appropriate in 
children continues to be complicated.  The research found shows that there are inherent 
risks in pharmacologic therapies for these lipid disorders; however the degree of these 
risks is still uncertain, especially over long periods of use.  On top of all of this, the 
decision of whether treatment should be initiated continues to remain complicated by the 
lack of long term data and proof that treatment in childhood actually reduces morbidity 
and mortality further down the road.  The studies show that these drugs are effective in 
lowering cholesterol in children; however it is unclear if they lower the incidence of or 
have any effect at all at preventing death and heart disease once these children reach 
adulthood.  Medication usage would need to be used for decades in order to determine if 
there is truly any reduction of cardiac mortality.  No study available comes close to 
following patients for that duration of time for efficacy or safety, making the decision to 
initiate therapy a difficult one to make based on current research. 
 Unfortunately, we are currently left wondering if these drugs truly reduce cardiac-
related mortality, and if the benefits actually outweigh the harms.  Ideally, pediatric 
patients being treated with lipid-lowering medications would be followed from initiation 
of therapy until death with regular physician monitoring for side effects, measurements of 
lipid levels, and autopsy to determine cause of death, and would be matched to control 
patients undergoing similar monitoring.  Obviously, this would be difficult to do from a 
monetary and feasibility standpoint, and has not been done to date.  Given the feasibility 
and difficulty of any prospective studies, harms data and longer term follow-up data may 
be more easily attainable and studied through retrospective review of large databases, 
such as an HMO database, that would likely contain millions of children and their 
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medical records.  A retrospective study like this would help reduce cost and be less time 
consuming, however retrospective reviews entail their own problems, especially with 
respect to limiting possible biases and capturing clinically relevant variables that are 
often missed. 
 The overall lack of current evidence for or against the use of these medications 
raises a larger point: How much evidence is needed before any new intervention should 
be used and incorporated into everyday practice?  Are short term studies for safety and 
efficacy sufficient to support the use of an intervention needed for a much longer time 
period? What size studies are sufficient to allow for implementation of interventions that 
will be used on a wide-scale basis? What type of studies must be done in order to prove 
an intervention is both safe and effective? Randomized controlled trials are often thought 
to be the “gold standard”, but are other study types acceptable? How “sure” must we be 
before we start and intervention?  
 These are all very relevant questions across all fields of medicine, and all are 
difficult to answer.  Many would immediately point to the meteoric rise and fall of the 
use of COX-2 inhibitors as a prime example of the need for more extensive research 
before incorporating an intervention into everyday practice. However, others could point 
to the use of penicillin or various vaccines as interventions that saved thousands of lives 
and are still used, despite their incorporation into “everyday” usage without extensive 
long-term research prior to their incorporation into routine care.  These examples are just 
a couple of the many that could be used to argue either side of this challenging issue, an 
issue that currently lacks a clear solution or immediate answers.  
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 Obviously, more research is preferred whenever possible before an intervention is 
initiated.  However, this research takes time, money, and effort that may not be readily 
available, especially when the intervention in question would be used over an extended 
period of time.  When the intervention in question could potentially save lives on a wide-
scale basis, the pressure to implement the intervention in question will continue to mount, 
even if research is not readily available.   
 In the face of the ongoing obesity epidemic and the millions of cardiac-related 
deaths annually, this is the case with screening for and treatment of dyslipidemias in 
children.  For the time being, decisions on whether to treat and screen for dyslipidemias 
continue to remain a complex but necessary decision that physicians face.  Given the lack 
of current evidence to the contrary and the recent recommendations by the AAP, the 
medications used to treat dyslipidemias will likely continue to be used.  However, should 
a physician decide to treat a child with abnormal serum lipid levels with medications, 
monitoring should be performed in order to assure that the medications are not causing 
otherwise avoidable harms.  Physicians should continue to check with both children and 
their parents for new physical complaints at routine visits. Lastly, children currently on 
these medications should continue to be followed, if possible into adulthood, to examine 
whether cardiac related morbidity and mortality are reduced in an effort to help shed 
further light on the subject.  
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APPENDIX I 
 
The Downs/Black Checklist for measuring study quality
[21]
. 
 
Reporting 
1. Is the hypothesis/aim/objective of the study clearly described? 
 
yes 1 
no 0 
 
2. Are the main outcomes to be measured clearly described in the Introduction or 
Methods section? 
If the main outcomes are first mentioned in the Results section, the question should be 
answered no. 
 
yes 1 
no 0 
 
3. Are the characteristics of the patients included in the study clearly described? 
In cohort studies and trials, inclusion and/or exclusion criteria should be given. In case-
control studies, a case-definition and the source for controls should be given. 
 
yes 1 
no 0 
 
4. Are the interventions of interest clearly described? 
Treatments and placebo (where relevant) that are to be compared should be clearly 
described. 
 
yes 1 
no 0 
 
5. Are the distributions of principal confounders in each group of subjects to be 
compared clearly described? 
A list of principal confounders is provided. 
 
yes 2 
partially 1 
no 0 
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6. Are the main findings of the study clearly described? 
Simple outcome data (including denominators and numerators) should be reported for all 
major findings so that the reader can check the major analyses and conclusions. (This 
question does not cover statistical tests which are considered below). 
 
yes 1 
no 0 
 
7. Does the study provide estimates of the random variability in the data for the main 
outcomes? 
In non-normally distributed data the inter-quartile range of results should be reported. In 
normally distributed data the standard error, standard deviation or confidence intervals 
should be reported. If the distribution of the data is not described, it must be assumed that 
the estimates used were appropriate and the question should be answered yes. 
 
yes 1 
no 0 
 
8. Have all important adverse events that may be a consequence of the intervention been 
reported? 
This should be answered yes if the study demonstrates that there was a comprehensive 
attempt to measure adverse events. (A list of possible adverse events is provided). 
 
yes 1 
no 0 
 
9. Have the characteristics of patients lost to follow-up been described? 
This should be answered yes where there were no losses to follow-up or where losses to 
follow-up were so small that findings would be unaffected by their inclusion. This should 
be answered no where a study does not report the number of patients lost to follow-up. 
 
yes 1 
no 0 
 
10. Have actual probability values been reported (e.g. 0.035 rather than <0.05) for the 
main outcomes except where the probability value is less than 0.001?  
 
yes 1 
no 0 
 
External validity 
All the following criteria attempt to address the representativeness of the findings of the 
study and whether they may be generalized to the population from which the study 
subjects were derived. 
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11. Were the subjects asked to participate in the study representative of the entire 
population from which they were recruited? 
The study must identify the source population for patients and describe how the patients 
were selected. Patients would be representative if they comprised the entire source 
population, an unselected sample of consecutive patients, or a random sample. Random 
sampling is only feasible where a list of all members of the relevant population exists. 
Where a study does not report the proportion of the source population from which the 
patients are derived, the question should be answered as unable to determine. 
 
yes 1 
no 0 
unable to determine 0 
 
12. Were those subjects who were prepared to participate representative of the entire 
population from which they were recruited? 
The proportion of those asked who agreed should be stated. Validation that the sample 
was representative would include demonstrating that the distribution of the main 
confounding factors was the same in the study sample and the source population. 
 
yes 1 
no 0 
unable to determine 0 
 
13. Were the staff, places, and facilities where the patients were treated, representative of 
the treatment the majority of patients receive? 
For the question to be answered yes the study should demonstrate that the intervention 
was representative of that in use in the source population. The question should be 
answered no if, for example, the intervention was undertaken in a specialist centre 
unrepresentative of the hospitals most of the source population would attend. 
 
yes 1 
no 0 
unable to determine 0 
 
Internal validity - bias 
14. Was an attempt made to blind study subjects to the intervention they have received? 
For studies where the patients would have no way of knowing which intervention they 
received, this should be answered yes. 
 
yes 1 
no 0 
unable to determine 0 
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15. Was an attempt made to blind those measuring the main outcomes of the 
intervention? 
 
yes 1 
no 0 
unable to determine 0 
 
16. If any of the results of the study were based on “data dredging”, was this made 
clear? 
Any analyses that had not been planned at the outset of the study should be clearly 
indicated. If no retrospective unplanned subgroup analyses were reported, then answer 
yes. 
 
yes 1 
no 0 
unable to determine 0 
 
17. In trials and cohort studies, do the analyses adjust for different lengths of follow-up 
of patients, or in case-control studies, is the time period between the intervention and 
outcome the same for cases and controls? 
Where follow-up was the same for all study patients the answer should yes. If different 
lengths of follow-up were adjusted for by, for example, survival analysis the answer 
should be yes. Studies where differences in follow-up are ignored should be answered no. 
 
yes 1 
no 0 
unable to determine 0 
 
18. Were the statistical tests used to assess the main outcomes appropriate? 
The statistical techniques used must be appropriate to the data. For example 
nonparametric methods should be used for small sample sizes. Where little statistical 
analysis has been undertaken but where there is no evidence of bias, the question should 
be answered yes. If the distribution of the data (normal or not) is not described it must be 
assumed that the estimates used were appropriate and the question should be answered 
yes. 
 
yes 1 
no 0 
unable to determine 0 
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19. Was compliance with the intervention/s reliable? 
Where there was non compliance with the allocated treatment or where there was 
contamination of one group, the question should be answered no. For studies where the 
effect of any misclassification was likely to bias any association to the null, the question 
should be answered yes. 
 
yes 1 
no 0 
unable to determine 0 
 
20. Were the main outcome measures used accurate (valid and reliable)? 
For studies where the outcome measures are clearly described, the question should be 
answered yes. For studies which refer to other work or that demonstrates the outcome 
measures are accurate, the question should be answered as yes. 
 
yes 1 
no 0 
unable to determine 0 
 
Internal validity - confounding (selection bias) 
21. Were the patients in different intervention groups (trials and cohort studies) or were 
the cases and controls (case-control studies) recruited from the same population? 
For example, patients for all comparison groups should be selected from the same 
hospital. The question should be answered unable to determine for cohort and case 
control studies where there is no information concerning the source of patients included 
in the study. 
 
yes 1 
no 0 
unable to determine 0 
 
22. Were study subjects in different intervention groups (trials and cohort studies) or 
were the cases and controls (case-control studies) recruited over the same period of 
time? 
For a study which does not specify the time period over which patients were recruited, 
the question should be answered as unable to determine. 
 
yes 1 
no 0 
unable to determine 0 
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23. Were study subjects randomized to intervention groups? 
Studies which state that subjects were randomized should be answered yes except where 
method of randomization would not ensure random allocation. For example alternate 
allocation would score no because it is predictable. 
 
yes 1 
no 0 
unable to determine 0 
 
24. Was the randomized intervention assignment concealed from both patients and health 
care staff until recruitment was complete and irrevocable? 
All non-randomized studies should be answered no. If assignment was concealed from 
patients but not from staff, it should be answered no. 
 
yes 1 
no 0 
unable to determine 0 
 
25. Was there adequate adjustment for confounding in the analyses from which the main 
findings were drawn? 
This question should be answered no for trials if: the main conclusions of the study were 
based on analyses of treatment rather than intention to treat; the distribution of known 
confounders in the different treatment groups was not described; or the distribution of 
known confounders differed between the treatment groups but was not taken into account 
in the analyses. In nonrandomized studies if the effect of the main confounders was not 
investigated or confounding was demonstrated but no adjustment was made in the final 
analyses the question should be answered as no. 
 
yes 1 
no 0 
unable to determine 0 
 
26. Were losses of patients to follow-up taken into account? 
If the numbers of patients lost to follow-up are not reported, the question should be 
answered as unable to determine. If the proportion lost to follow-up was too small to 
affect the main findings, the question should be answered yes. 
 
yes 1 
no 0 
unable to determine 0 
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Power 
27. Did the study have sufficient power to detect a clinically important effect where the 
probability value for a difference being due to chance is less than 5%? 
Sample sizes have been calculated to detect a difference of x% and y%. 
 
Size of smallest intervention group 
A <n1 
0 
B n1–n2 1 
C n3–n4 2 
D n5–n6 3 
E n7–n8 4 
F n8+ 5 
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